Table 1

Current European and Canadian guideline recommendations for lipids, lipoproteins, and baseline levels for study participants
Parameter Subjects without AVD Subjects with AVD
Guidelines Treatment group Guidelines Treatment group
CCS* EUhigh risk E + A10 A20 CCS* EU very high risk E + A10 A20
n = 66 n = 67 n = 449 n = 448
LDL-C (mmol/L) ≤2.0 or <2.5 3.25 (0.55) 3.11 (0.53) ≤2.0 or <1.8 2.58 (0.70) 2.56 (0.49)
↓50% ↓50% or ↓50%
Non-HDL-C (mmol/L) ≤2.6 <3.3 4.04 (0.64) 3.84 (0.65) ≤2.6 <2.6 3.21 (0.76) 3.21 (0.61)
Apo B (g/L) ≤0.8 <1.0 1.2 (0.2) 1.1 (0.2) ≤0.8 <0.8 1.0 (0.2) 1.0 (0.2)

Baseline lipid and lipoprotein levels were determined for parameters common to CCS2012 and EU2012 targets.

A 10/20, atorvastatin 10 or 20 mg; Apo, apolipoprotein; AVD, atherosclerotic vascular disease; CCS, Canadian Cardiovascular Society guidelines (2012); E, ezetimibe 10 mg; EU, European Guidelines (2012); LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol.

*Canadian guidelines specify that treatment targets should not change based on risk assessment.

European guidelines state that total cholesterol should be considered a treatment target if other analyses are not available.

n may vary slightly between measured parameters due to differences in available data.

Constance et al.

Constance et al. Lipids in Health and Disease 2014 13:13   doi:10.1186/1476-511X-13-13

Open Data